Fewer infants than older patients in paediatric randomised controlled trials

François Angoulvant1, Florentia Kaguelidou, Stephane Dauger

  • 1AP-HP, Hôpital Robert Debré, Université Denis Diderot-Paris VII, Unité INSERM CIE5, 48 bd Sérurier, 75019, Paris, France. francois.angoulvant@rdb.aphp.fr

Insights

Paediatric randomised controlled trials (PRCTs) often exclude newborns and infants. This study found younger children were underrepresented in PRCTs, highlighting a need for more research in these vulnerable populations.

Area of Science:

  • Clinical Research
  • Paediatric Medicine
  • Evidence-Based Practice

Background:

  • Paediatric randomised controlled trials (PRCTs) are crucial for advancing child health.
  • Concerns exist regarding the underrepresentation of the youngest age groups in clinical research.

Purpose of the Study:

  • To assess the inclusion of different age groups, particularly newborns and infants, in PRCTs.
  • To identify trends in paediatric trial recruitment over time.

Main Methods:

  • A PubMed search was conducted for PRCTs published in leading medical journals in 2006 and 2009.
  • 144 articles from 2006 and 66 from 2009 were randomly selected and analyzed for age characteristics, study design, and topic.
  • The proportion of trials including newborns, infants, children, and adolescents was determined.

Main Results:

  • In 2006, only 11% of PRCTs included newborns and 26% included infants.
  • By 2009, trial inclusion for newborns rose to 17% and for infants to 24%.
  • Respiratory diseases, infectious diseases, and mental/behavioural disorders were the most common study topics.

Conclusions:

  • PRCTs in leading journals significantly underrepresent newborns and infants compared to older children.
  • Increased efforts are necessary to promote research involving the youngest paediatric populations.
  • Further investigation into the impact of recent regulations on paediatric drug trials is warranted.

Related Concept Videos

Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...